Core 2 biomarkers, consisting of changes in MTBR-tau243, p-tau205, or positive tau-PET, are not used for initial diagnosis (although they are highly associated with Aβ pathology and are considered sufficient to rule in AD), and serve mainly to stage disease severity and inform on the rate of progression [15]. Here, MAPT is linked to Alzheimer disease.